Transcranial random noise stimulation for the acute treatment of depression: a randomized controlled trial

Stevan Nikolin[1,2], Angelo Alonzo[1,2], Donel Martin[1,2], Veronica Gálvez [1,3], Sara Buten[1,4], Rohan Taylor[1,5], James Goldstein[6], Cristal Oxley[7], Dusan Hadzi-Pavlovic[1], Colleen K. Loo[1,2,8]

[1] School of Psychiatry, University of New South Wales, Sydney, Australia

[2] Black Dog Institute, Sydney, Australia

[3] Mental Health Department, Parc Taulí University Hospital, Institut d'Investigació I Innovació Sanitària Parc Taulí (I3PT), Barcelona, Spain

[4] Prince of Wales Hospital, Sydney, Australia

[5] Concord Centre for Mental Health, Concord, Australia

[6] Currumbin Clinic, Currumbin, Australia

[7] Department of Child and Adolescent Psychiatry, Michael Rutter Centre – South London and Maudsley NHS Foundation Trust, UK

[8] St. George Hospital, Sydney, Australia

Abstract

Background

Transcranial electrical stimulation has broad potential as a treatment for depression. Transcranial random noise stimulation (tRNS), which delivers randomly fluctuating current intensities, may have greater cortical excitatory effects compared to other forms of transcranial electrical stimulation. We therefore aimed to investigate the antidepressant efficacy of tRNS.

Methods

Depressed participants were randomly assigned by computer number generator to receive 20 sessions of either active or sham tRNS over four weeks in a double-blinded, parallel group randomized-controlled trial. tRNS was delivered for 30mins with a direct current offset of 2mA and a random noise range of 2mA. Primary analyses assessed changes in depression severity using the Montgomery-Asperg Depression Rating Scale (MADRS). Neuroplasticity, neuropsychological, and safety outcomes were analysed as secondary measures.

Results

69 participants were randomised, of which three discontinued treatment early leaving 66 (sham n = 34, active n = 32) for per-protocol analysis. Depression severity scores reduced in both groups (MADRS reduction in sham = 7.0 [95%CI 5.0-8.9]; and active = 5.2 [95%CI 3.2-7.3]). However, there were no differences between active and sham groups in the reduction of depressive symptoms, or the number of participants meeting response (sham = 14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%). Erythema, paraesthesia, fatigue, and dizziness/light-headedness occurred more frequently in the active tRNS group. Neuroplasticity, neuropsychological and acute cognitive effects were comparable between groups.

Conclusion

Our results do not support the use of tRNS with the current stimulation parameters as a therapeutic intervention for the treatment of depression.

Clinical Trial Registration:

Clinical registration was obtained on the 15th February 2013 from clinicaltrials.gov (NCT01792414) after recruitment of the first study participant on the 30th January 2013, but prior to the participant's completion of the four week sham-controlled phase of the trial. All remaining participants were recruited following clinical registration.

Funding: NHMRC project grant APP1051423

Keywords:

- Transcranial Random Noise Stimulation
- Electric Stimulation Therapy [E02.331]
- Depression [F01.145.126.350]
- Randomized Controlled Trial [V03.175.250.500.500]

57 # Introduction

58 Although there are a number of established treatments for depression, a sizeable
59 proportion of patients still fail to adequately respond, with a conservative estimate of
60 approximately one-third of these not reaching remission even after four trials of different
61 antidepressant medication classes (Rush et al., 2006). In addition, many patients fail to
62 complete a course of antidepressants due to side effects (Trivedi et al., 2006). While
63 electroconvulsive therapy (ECT) remains the most effective treatment, with response rates of
64 up to 70% (Haq et al., 2015), treatment uptake and adherence can be limited by patient
65 concerns over possible cognitive side effects and the need for general anaesthetic. Thus, there
66 has been interest in the development of novel, non-convulsive brain stimulation techniques
67 that are well-tolerated and have a benign side effect profile, such as transcranial electrical
68 stimulation. These neuromodulatory techniques could have the greatest potential for
69 translation into widespread clinical use, being relatively inexpensive, easy to use, portable,
70 and safe (Bikson et al., 2016; Nikolin et al., 2017). Here we report an investigation of the
71 efficacy of one such technique, transcranial random noise stimulation (tRNS), for the
72 treatment of depression.

73 Transcranial electrical stimulation involves applying a weak electrical current to
74 cerebral tissue via scalp electrodes, resulting in modulation of neuronal membrane potentials
75 and spontaneous firing rates (Nitsche et al., 2008) that can lead to long term changes in
76 cortical excitability and plasticity (Nitsche and Paulus, 2001; Player et al., 2014a). Applying
77 a direct current between the electrodes, referred to as transcranial direct current stimulation
78 (tDCS), has been demonstrated to have antidepressant effects in clinical trials (Loo et al.,
79 2012a; Brunoni et al., 2013b; Brunoni et al., 2017). Recent meta-analyses of randomised,
80 sham-controlled trials have found tDCS to be more effective than sham stimulation, with

81 significantly higher remission and response rates as well as a greater reduction in depressive
82 symptoms (Brunoni et al., 2016; Mutz et al., 2018). As depression has increasingly been
83 conceptualised as a disorder underpinned by disrupted neuroplasticity (Pittenger and Duman,
84 2008; Liu et al., 2017), cumulative changes to synaptic functioning may underlie the
85 therapeutic effects observed in clinical trials of tDCS (Szymkowicz et al., 2016). Modifying
86 stimulation parameters to enhance cortical excitability effects may therefore present a
87 pathway to increase treatment efficacy.

88 tRNS is a more recently developed transcranial electrical stimulation technique that
89 involves randomly fluctuating current intensities over a broad frequency spectrum (between
90 0.1 to 640 Hz). There is some evidence that tRNS has comparable, if not greater, cortical
91 excitatory effects as compared to tDCS (Moliadze et al., 2014; Ho et al., 2015b; Inukai et al.,
92 2016). A single session of 10 minutes of 1 milliampere (mA) tRNS to the motor cortex has
93 been found to produce a greater increase in cortical excitability than tDCS, lasting up to 60
94 minutes beyond the stimulation period (Moliadze et al., 2014; Inukai et al., 2016), although
95 tDCS may lead to a longer period of excitation of at least 90 minutes post-stimulation
96 (Moliadze et al., 2014). tRNS may also be applied with a direct current offset so that the
97 stimulation incorporates neuromodulatory features of tDCS, in addition to limiting
98 homeostatic responses via randomly fluctuating current intensities. Results from Ho et al.
99 (2015b) suggest that tRNS with a direct current offset may be more effective in increasing
100 motor cortical excitability than the more common application of tRNS without an offset.

101 There has been a burgeoning growth in recent years of studies investigating the
102 application of tRNS to enhance sensory processing (Ghin et al., 2018; Rufener et al., 2018;
103 Contemori et al., 2019), motor performance (Abe et al., 2019; Jooss et al., 2019), and
104 cognition (Snowball et al., 2013; Popescu et al., 2016; Mammarella et al., 2017; Shalev et al.,
105 2018; Tyler et al., 2018) in healthy participants with largely promising results. To date,

106 however, few studies have examined the effectiveness of tRNS for clinical/therapeutic uses,
107 with such studies typically characterised by small sample sizes and/or varying efficacy (Chan
108 et al., 2012; Haesebaert et al., 2014; Palm et al., 2016a; Hayward et al., 2017; Kreuzer et al.,
109 2017; Salemi et al., 2019). Regarding the effects of tRNS on mood, there is currently only
110 one report involving treatment of major depressive disorder (MDD). Chan et al. (2012)
111 reported a case of a patient diagnosed with MDD who had responded to two trials of tDCS (2
112 mA, 20 minutes, 15 sessions over 3 weeks) prior to trialling a 4-week course of open-label
113 tRNS (2 mA range with 1 mA direct current offset, 20 sessions lasting 20 minutes each). It
114 was found that by the 15th session, there was a 63% reduction from baseline in the severity of
115 depressive symptoms, compared with a reduction of 31% and 25% at the end of the acute
116 treatment phase in the two prior trials of tDCS. For all three trials, depression scores at
117 baseline were similar but the patient reported faster improvement with tRNS and lesser skin
118 sensations compared to tDCS. Given this encouraging case report finding, and the potential
119 theoretical advantages of tRNS relative to tDCS, further investigation of the antidepressant
120 effects of tRNS is warranted.
121 The primary aim of this study, therefore, was to conduct the first randomised, sham-
122 controlled trial of tRNS in depression. It was hypothesised that tRNS would have significant
123 antidepressant efficacy compared with a sham control over a 4-week treatment phase. A
124 secondary aim of this study was to examine whether antidepressant effects of tRNS were
125 mediated by restoration of brain neuroplasticity. We hypothesised that antidepressant
126 response to tRNS would be associated with increased brain plasticity, given prior findings of
127 reduced neuroplasticity in depressed individuals compared to healthy matched controls
128 (Player et al., 2013), and findings suggesting a normalisation of neuroplasticity following
129 antidepressant treatment using tDCS (Player et al., 2014b). Lastly, as this is the first treatment
130 trial of tRNS for depression, a comprehensive neuropsychological test battery was designed

specifically to be sensitive to symptom changes, measure any adverse cognitive effects, and to assess any potential acute cognitive enhancing effects.

Materials and Methods

Trial design

The main study phase used a double-blinded, parallel, randomized, sham-controlled design. Participants were assigned by a computer-generated random number sequence to one of two groups: active tRNS or sham tRNS. Randomization was stratified according to whether participants were diagnosed with unipolar or bipolar depression. Participants were required to attend a total of 20 tRNS sessions over four weeks conducted on consecutive weekdays during the sham-controlled phase. Participants who missed five or more sessions during the sham-controlled phase were withdrawn from the trial, and were excluded from analyses using a per-protocol approach. All participants were offered an additional 20 sessions of open-label active tRNS over four weeks, also administered every weekday. After treatment in the acute daily treatment phases, participants entered a taper phase during which they received once weekly tRNS treatment for four weeks with the final taper session coinciding with a 1-month follow-up visit. Participants were then followed up at 3, 6 and 9 months. Participants and raters were blinded to tRNS condition and blinding was maintained until the study was completed and the dataset locked.

Mood, neuroplasticity, and neuropsychological function were assessed at the intervals shown in Supplementary Table S1. Adequacy of blinding to treatment was assessed at the end of the sham-controlled phase by asking participants and raters to guess the tRNS condition administered during the first four weeks of treatment. To investigate whether treatment expectations may be a predictor of response, participants completed the Treatment

154 Expectancy Questionnaire (TEQ; see Supplementary Figure S1) at baseline before the first
155 tRNS session.
156 The study was powered for the primary aim of testing efficacy over the sham-
157 controlled phase. From pilot data, it was assumed that tRNS would be at least as effective as
158 tDCS when tested in a sham-controlled trial, given that sampling criteria were very similar.
159 Means and standard deviations of the active and sham treatment groups from our previous,
160 sham-controlled, 3-week trial of tDCS (Loo et al., 2012b) were used, with outcomes
161 extrapolated for a 4-week comparison period. This resulted in an effect size of Cohen's d =
162 0.7. For 80% power and $\alpha = 0.05$, a sample of 33 subjects per group was required to
163 demonstrate a difference between active and sham treatment.
164

165 ## Participants

166 At study entry, participants were at least 18 years old; in a current major depressive
167 episode (as part of a MDD or Bipolar Disorder) of a minimum four weeks duration, defined
168 according to Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text
169 revision; DSM-IV-TR) criteria and established using the Mini International Neuropsychiatric
170 Interview (MINI; Version 5.0.0) (Sheehan et al., 1998) and study clinician assessment; and
171 had a total score of at least 20 on the Montgomery-Asberg Depression Rating Scale
172 (MADRS) (Montgomery and Asberg, 1979). Participants were free of antidepressant
173 medications, or continued on stable doses of antidepressant medications to which they had
174 failed to respond after an adequate course of treatment, with dosage unchanged for at least
175 four weeks prior to study entry. Bipolar participants were required to be on a mood stabilizer
176 medication (e.g. lithium) as prophylaxis against treatment-emergent mania or hypomania for
177 the duration of the study.

178 Exclusion criteria included: psychotic disorder as per DSM-IV-TR; drug or alcohol
179 abuse or dependence within 12 months of study entry; inadequate response to ECT in the
180 current depressive episode; current benzodiazepine medication; rapid clinical response
181 required (e.g., due to high suicide risk); clinically defined neurological disorder or insult;
182 metal in the cranium; skull defects; skin lesions on the scalp at electrode sites; or pregnancy.
183 The study was approved by the human research ethics committee of the University of
184 New South Wales and was conducted at the Black Dog Institute in Sydney, Australia.
185 Participants provided written informed consent for this study. Recruitment began in January
186 2013 and the last follow-up was conducted in 2017. The study was registered with the
187 ClinicalTrials.gov website (Identifier: NCT01792414).
188

189 ## Transcranial random noise stimulation

190 A DC-Stimulator Plus device (NeuroConn GmbH, Germany) applied high frequency
191 tRNS (100-640 Hz) via two 7 x 5 cm saline-soaked sponge-covered electrodes held in
192 position by a headband. Active tRNS was administered for 30 mins per session with a range
193 of 2 mA and an offset of 2 mA. The anode was placed over F3 (as per the 10-20 international
194 electroencephalogram system), corresponding to the left dorsolateral prefrontal cortex
195 (LDLPFC), and the cathode over F8. For sham stimulation, the current was ramped up over
196 10 s, left on for 30 s, then gradually ramped down over 10 s, so that both treatment groups
197 experienced an initial tingling sensation. The tRNS machine was then left on until the end of
198 the session to preserve blinding. This sham procedure resulted in adequate blinding for tDCS
199 in previous trials (e.g., (Loo et al., 2010; Loo et al., 2012b)), and was therefore expected to be
200 sufficient for tRNS, which produces milder skin sensations compared to tDCS (Ambrus et al.,
201 2010). Participants were comfortably seated at rest and did not engage in any particular tasks
202 during stimulation.

Clinical outcome measures

The primary outcome measure for comparing active and sham tRNS was the MADRS, which was administered by trained raters with established inter-rater reliability (intraclass correlation coefficient > 0.7). Secondary measures were the Clinician Global Impression – Improvement (CGI-I) (Guy, 1976), Beck Depression Inventory (BDI-II) (Beck et al., 1996) and Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form (Q-LES-SF) (Endicott et al., 1993) scales.

Neuroplasticity outcome measures

As an optional study offered to participants in the main tRNS trial, a paired associative stimulation (PAS) paradigm previously described in Player et al. (2012) was used to assess the effects of tRNS on neuroplasticity. The PAS testing was conducted at baseline before the first tRNS session, and again after completion of the sham-controlled and open-label phases. Briefly, the PAS paradigm involves measuring motor evoked potentials (MEPs) following single-pulse transcranial magnetic stimulation (TMS) via electromyography (EMG) before and after applying a stimulation protocol (i.e., PAS) to the motor cortex to assess changes in motor cortical excitability (see the Supplementary Material for a detailed description of PAS methodology).

Neuropsychological outcome measures

The following neuropsychological battery was administered to comprehensively assess cognitive function: California Verbal Learning Test-II (CVLT-II) (Delis et al., 2000) – verbal learning and memory; Ruff 2 & 7 (Ruff and Allen, 1996) – attention processes; Wechsler Adult Intelligence Scale-IV edition (WAIS-IV) Digit Span subtest (Wechsler,

228 2008) – simple auditory attention and working memory; Symbol Digit Modality Test
229 (SDMT) (Smith, 1991) – psychomotor processing speed; Delis-Kaplan Executive Function
230 System (D-KEFS) Verbal Fluency test (Delis et al., 2001) – phonemic fluency, semantic
231 fluency, cognitive flexibility; and Cognitive Failures Questionnaire (Broadbent et al., 1982) –
232 subjective cognitive functioning. Alternative versions of the CVLT-II, D-KEFS Verbal
233 Fluency, and SDMT were used to minimize practice effects. In addition, computer
234 administered cognitive tests were used to assess safety and acute effects. A simple reaction
235 time test, in which participants were instructed to press a space bar as soon as they saw a
236 cross appear in the middle of a computer screen, was administered immediately before and
237 after the first tRNS session. An Emotion Recognition Task (Montagne et al., 2007), which
238 assessed recognition of six basic facial emotions, was also administered after the first tRNS
239 session.
240

241 ## Physical adverse events

242 As an additional safety outcome measure, physical adverse events were assessed each
243 session using a tRNS Side Effects Questionnaire (Supplementary Figure S2), adapted from
244 Brunoni et al. (2011), which collected information regarding the type of adverse event, its
245 severity, and its causality.

246

247 ## Statistical Analyses

248 All statistical analyses were conducted using SPSS software (IBM SPSS Statistics 25
249 for Windows; SPSS Inc.). Outcome measures were analysed for change over the sham-
250 controlled phase using a mixed-effects repeated measures (MERM) model with a restricted
251 number of covariates. Time was entered as a repeated measures factor with an unstructured
252 covariance matrix, tRNS Condition (active or sham) was a between-subjects factor, and

253 subjects were included as a random effect. For mood and quality of life outcomes, covariates
254 were selected based on prior reports of their significant effect on antidepressant response to
255 transcranial electrical stimulation; these included treatment resistance (Brunoni et al., 2016)
256 (assessed by the Maudsley Staging Method (Fekadu et al., 2009)), and presence of concurrent
257 antidepressant medications (Brunoni et al., 2013a; Brunoni et al., 2013c). A MERM model
258 was similarly used for neuropsychological outcomes, with MADRS mood scores at the
259 respective time points included as a covariate. Acute cognitive effects following the first
260 session were examined using a two-way repeated measure analysis of variance
261 (RMANOVA), with factors of tRNS Condition and Time (pre and post session 1). For the
262 Emotion Recognition Task, a multivariate ANOVA (MANOVA) was conducted with the
263 between-subject factor of tRNS Condition.

264 Additional MERM analyses were conducted for the primary outcome measure
265 (MADRS). Baseline scores on the TEQ were added as a covariate to the MERM analysis to
266 test whether treatment expectations modified mood outcomes. To assess whether medication
267 use affected outcomes, each medication class (antidepressants, benzodiazepines,
268 antipsychotics, lithium and anticonvulsants) was entered as the only covariate in separate
269 MERM analyses.

270 The number of responders (defined as a reduction in MADRS total score of ≥ 50%
271 from baseline) and remitters (defined as a final MADRS total score < 10) at the end of the
272 sham-controlled phase were compared between active and sham tRNS groups using a
273 Fisher's exact test.

274 The association between participant or rater guesses (active or sham) and the
275 participant's assigned tRNS condition (active or sham) was tested using a Pearson Chi-square
276 test with Yates' continuity correction. Cohen's kappa statistic was used to assess agreement
277 between participant and rater guesses.

278 Statistical tests were two-tailed and significance was set at $p < 0.05$.

279

280 Results

281 A total of 69 participants met inclusion criteria and were randomized to receive either active
282 or sham tRNS during the sham-controlled phase (see the CONSORT flow diagram,
283 Supplementary Figure S3). A total of 66 participants (sham: 34, active: 32) completed the
284 sham-controlled phase and were analysed using a per-protocol approach. Table 1 shows
285 demographic and clinical characteristics for active and sham tRNS groups at baseline.

286 **Table 1. Comparison of demographic and clinical characteristics at baseline.**

	Sham	Active
n	34	32
Medications (yes/no)		
Any concurrent medication	27/7	22/10
Antidepressant	23/11	20/12
Lithium	1/33	2/30
Benzodiazepine*	2/32	2/30
Antipsychotic	6/28	4/28
Anticonvulsant	5/29	1/31
Clincial and demographic variables (m, SD)		
Gender (m/f)	19/15	17/15
Melancholic (yes/no)	19/9	12/12
MDD/BP1/BP2	30/3/1	30/0/2
Age (years)	48.8 (12.3)	47.5 (12.0)
Age at onset (years)	27.0 (9.6)	27.5 (9.6)
Duration of current episode (months)	24.4 (32.2)	37.2 (48.0)
Duration of previous episodes (months)	65.9 (65.8)	88.5 (93.6)
Antidepressants failed current episode	2.1 (1.7)	2.6 (2.9)
Total lifetime failed antidepressants	4.0 (3.0)	5.0 (5.1)
Maudsley Staging score	7.3 (2.1)	6.5 (1.9)
Baseline MADRS score	29.5 (4.6)	30.1 (5.0)
Baseline BDI-II score	33.8 (9.1)	34.1 (9.4)
Baseline CGI-S score	4.4 (0.6)	4.4 (0.6)
Baseline Q-LES-SF score	32.8 (10.5)	34.9 (11.2)
Baseline TEQ score	24.5 (7.6)	24.1 (7.1)

287 *Participants were required to cease benzodiazepine medication use prior to commencing the trial.

MDD: Major depressive disorder. BP1/BP2: Bipolar I and bipolar II disorder. MADRS: Montgomery-Asberg Depression Rating Scale. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. BDI-II: Beck Depression Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale ranked from 1-normal to 7-extremely ill. TEQ: Treatment Expectancy Questionnaire.

Clinical outcome measures

Table 2 shows the results for all MERM analyses of mood and quality of life outcome measures during the sham-controlled phase. MERM analysis of MADRS scores showed a significant effect of Time ($p < 0.001$). There was, however, no effect of tRNS Condition ($p = 0.630$), and no significant Time × Condition interaction ($p = 0.445$; see Figure 1). Results from intention-to-treat analyses are also reported for all planned outcomes in Supplementary Table S2, in accordance with CONSORT guidelines for parallel group randomised control trials (Schulz et al., 2010). Repeating the analysis while incorporating scores from the Treatment Expectations Questionnaire as an additional covariate did not modify outcomes. Concurrent medications did not significantly affect outcomes when entered as covariates in separate MERM analyses (see Supplementary Table S3). Supplementary Table S4 shows results from MERM analyses of all outcome measures acquired during the acute daily treatment phases combined (i.e. both sham-controlled and open-label phases). Supplementary Figure S4 shows graphs of mood and quality of life measures for all time-points up to the 9-month follow-up assessment.

One participant in the active tRNS group (3.1%), and five participants receiving sham tRNS (14.7%), were considered treatment responders after completion of the sham-controlled phase (i.e. following 20 sessions of tRNS). Only two participants met the remission criterion, both in the sham tRNS condition (5.9%). Fisher's exact tests revealed no statistically significant differences between active and sham tRNS conditions for response ($p = 0.198$) and remission ($p = 0.493$) rates.



315

316 **Figure 1. Mood scores.** Graph showing MADRS scores (estimated marginal means ±
317 SD) across rating time points, including the sham-controlled phase (from baseline to 4-
318 weeks), open-label phase (from 4 – 8 weeks), and 1-month follow-up assessment following
319 the final taper session. Dotted lines indicate sham tRNS sessions delivered during the sham-
320 controlled phase.

321 **Table 2. Mood and quality of life outcome measures.** Estimated marginal means and results from MERM analyses during the
322 sham-controlled phase. MERM analyses were performed including the following covariates: Maudsley staging method total score as a
323 measure of treatment resistance, and antidepressant use.

	Baseline		Week 2		Week 4		Condition		Time		Time × Condition	
Mood Assessments (m, SEM)	Sham	Active	Sham	Active	Sham	Active	F	p	F	p	F	p
MADRS	29.1 (0.8)	28.9 (0.8)	24.4 (1.0)	24.8 (1.1)	22.1 (1.2)	23.7 (1.3)	0.24	0.630	41.73	**<0.001**	0.82	0.445
BDI-II	32.6 (1.7)	33.2 (1.8)	25.2 (1.9)	27.2 (2.0)	22.1 (1.9)	24.9 (2.0)	0.72	0.399	24.56	**<0.001**	0.46	0.762
CGI-I	-	-	3.5 (0.1)	3.6 (0.1)	3.1 (0.1)	3.4 (0.1)	2.24	0.140	12.69	**<0.001**	2.10	0.153
Q-LES-SF	32.4 (1.9)	36.0 (2.1)	-	-	43.5 (2.8)	43.9 (2.9)	0.45	0.503	31.67	**<0.001**	0.84	0.362

324 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale
325 ranked from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. m: Mean. SEM: Standard error of measure.
326

Neuroplasticity outcome measures

A total of 44 participants (sham: 25, active: 19) completed the optional PAS study to assess changes in motor cortical excitability. A MERM analysis found no significant effects of Time ($p = 0.209$) or Condition ($p = 0.780$), and no significant Time × Condition interaction ($p = 0.570$; see Table 3, and Supplementary Figure S5). Furthermore, change in MADRS scores did not correlate with changes in MEP amplitudes from baseline to the end of the sham-controlled phase ($r = -0.02$, $p = 0.905$; Supplementary Figure S6).

Neuropsychological outcomes

Neuropsychological outcomes during the sham-controlled phase are shown in Table 3. There were no significant main effects of Time, and no significant Time × Condition interaction effects for all neuropsychological measures.

339 **Table 3. Neuroplasticity and neuropsychological outcome measures.** Estimated marginal means and results from MERM analyses
340 during the sham-controlled phase. The neuroplasticity MERM analysis were performed including the following covariates: Maudsley staging
341 parameters total score as a measure of treatment resistance, and antidepressant use. Neuropsychological MERM analyses were performed using
342 MADRS scores as a covariate.

	Baseline		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	F	p	F	p	F	p
Neuroplasticity Assessment (m, SEM)										
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	1.31 (0.09)	1.40 (0.10)	0.08	0.780	1.63	0.209	0.33	0.570
Neuropsychological Assessments (m, SEM)										
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.8)	48.7 (2.2)	46.3 (2.3)	49.7 (2.2)	2.12	0.148	0.12	0.734	0.01	0.913
CVLT-II: Long delay free recall z-score	-0.41 (0.21)	0.03 (0.22)	-0.64 (0.22)	-0.38 (0.21)	2.69	0.104	1.85	0.176	0.20	0.653
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.5 (0.7)	10.9 (0.7)	11.9 (0.7)	0.97	0.327	0.01	0.945	0.32	0.575
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	9.8 (0.8)	11.8 (0.8)	2.84	0.094	0.05	0.828	0.80	0.372
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.1 (0.6)	9.6 (0.6)	10.6 (0.6)	3.36	0.069	0.50	0.480	0.02	0.888
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	49.9 (1.9)	51.3 (1.9)	53.6 (1.8)	1.66	0.200	3.45	0.066	0.01	0.946
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.6 (2.4)	50.4 (2.4)	48.7 (2.3)	1.02	0.316	0.34	0.561	0.08	0.779
SDMT: Total correct z-score	-0.31 (0.18)	0.25 (0.18)	-0.02 (0.19)	0.41 (0.18)	7.78	**0.006**	1.32	0.254	0.15	0.703
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.6)	10.5 (0.6)	12.6 (0.5)	13.00	**<0.001**	2.57	0.112	0.12	0.732
CFQ: Total score	50.0 (2.2)	46.8 (2.3)	49.9 (2.3)	50.0 (2.2)	0.52	0.474	0.40	0.528	0.57	0.451

343 PAS: Paired associative stimulation. MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test.
344 D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measure.
345

Acute cognitive effects

For reaction time, the main effects of Time ($p = 0.404$), Condition ($p = 0.992$), and the Time × Condition interaction effect ($p = 0.949$) were not statistically significant. Further, for the Emotion Recognition Task the main effect of tRNS Condition was not statistically significant ($p = 0.347$).

Physical adverse events

Adverse events occurring during the sham-controlled and open-label phases of the trial are presented in Table 4. Side-effects were transient and mild-to-moderate in severity. Pearson Chi-square tests revealed significantly more instances of erythema (skin redness; $p < 0.001$), paraesthesia (tingling, burning, and itching sensations; $p < 0.001$), fatigue ($p = 0.006$), and dizziness/light-headedness ($p = 0.002$) following active tRNS as compared to sham tRNS sessions.

Table 4. Physical adverse event frequency. Adverse events are sorted according to overall likelihood of occurrence, with events most likely to occur listed first. Differences in frequency of adverse event occurrence during the sham-controlled phase was tested using Pearson Chi-square tests with Yates' continuity correction.

	Sham-controlled phase						Open-label phase	
	Sham (646 sessions)		Active (650 sessions)		Pearson Chi-square		Active (1161 sessions)	
	n	%	n	%	$\chi2$	*p*-value	n	%
Erythema	129	20.0	454	69.8	323.67	**<0.001**	781	67.3
Tingling	126	19.5	332	51.1	139.96	**<0.001**	623	53.7
Burning	15	2.3	251	38.6	214.14	**<0.001**	370	31.9
Itching	40	6.2	97	14.9	25.21	**<0.001**	170	14.6
Fatigue	33	5.1	60	9.2	7.66	**0.006**	75	6.5
Headache	43	6.7	30	4.6	2.17	0.141	31	2.7
Dizziness/light-headedness	10	1.5	31	4.8	9.95	**0.002**	48	4.1
Nausea	7	1.1	15	2.3	2.22	0.136	36	3.1
Scalp Discomfort	7	1.1	9	1.4	0.06	0.811	10	0.9
Other	14	2.2	26	4.0	3.05	0.081	58	5.0

Blinding integrity

Participants were asked to guess their treatment condition at the end of the double-blinded sham-controlled phase. 75% of participants in the sham condition correctly guessed they received sham tRNS, and 55% of participants in the active condition correctly guessed they had received active tRNS. A Pearson Chi-square test of participant guesses was significant ($\chi^2 = 4.68$; $p = 0.031$), suggesting that participants were not adequately blinded to their treatment condition. To determine whether participant guesses of treatment condition may have influenced mood outcomes, we performed a post-hoc simple linear regression analysis; percent change in MADRS score over the 4-week sham-controlled phase was selected as the dependent variable, and participant guess (active, sham) as the independent variable. This analysis was not statistically significant ($R^2 = 0.023$, $F = 1.43$, $p = 0.237$).

Blinded study raters were similarly asked to guess participants' treatment condition at the end of the sham-controlled phase. Raters correctly guessed that participants had received sham tRNS 56% of the time, and active tRNS 31% of the time. A Pearson Chi-square test found this difference not to be statistically significant ($\chi^2 = 0.492$; $p = 0.483$). Furthermore, Cohen's kappa showed no agreement between participant and rater guesses ($\kappa = 0.134$; $p = 0.329$).

381 ## Discussion

382 Here we report the results of the first randomized control trial to examine the efficacy
383 of tRNS for the treatment of depression. Although there was a significant reduction of
384 depressive symptoms over the duration of the study period, there was no difference in the rate
385 of improvement between sham and active tRNS conditions. Further, there was no significant
386 effect of tRNS on neuroplasticity measures in the subset of participants that completed the
387 PAS paradigm, suggesting that stimulation did not increase global cortical excitability. tRNS
388 was found to be safe with no adverse acute cognitive, neuropsychological or severe phyisical
389 side effects. However, tRNS resulted in a higher incidence rate of skin redness (erythema)
390 and paraesthesia (tingling, itching, and burning sensations) in the active condition, as well as
391 fatigue and dizziness/light-headedness, which occurred in fewer than 10% of sessions.
392 Nevertheless, the stimulation protocol was well-tolerated with only one participant dropping-
393 out due to adverse effects, which were not conclusively associated with tRNS.

394 The results of this study do not support the use of tRNS with the current stimulation
395 parameters as a therapeutic intervention for the treatment of depression. Despite encouraging
396 initial evidence of significant reductions in depression scores in patients with fibromyalgia
397 (Curatolo et al., 2017), and a case report of improvement in MDD (Chan et al., 2012), mood
398 and quality of life outcomes in the active tRNS group were no different from the placebo-
399 controlled response in the sham group at all time-points. The size of reductions in depressive
400 symptoms observed in both conditions of the present study is broadly similar to the sham
401 condition of previous trials of tDCS for depression (Blumberger et al., 2012; Loo et al.,
402 2012a; Palm et al., 2012; Brunoni et al., 2013b; Bennabi et al., 2015). Of these previous
403 tDCS trials, our study design was most similar to a recent international multisite investigation
404 conducted by our group, which observed improvements in depression scores of 27.8% and
405 22.3% in sham and active tDCS conditions, respectively, as compared to 24.1% and 18.0% in

406 sham and active tRNS conditions (Loo et al., 2018). We recruited participants using
407 analogous inclusion/exclusion criteria, participant demographic and clinical characteristics,
408 and adopted comparable stimulation parameters, at least in terms of treatment duration (30
409 minutes), session number and frequency (20 daily weekday sessions), and direct current
410 intensity (2 mA direct current offset in the present study *vs* a marginally stronger current
411 intensity of 2.5 mA in the tDCS study). Interestingly, the present tRNS trial and Loo et al.
412 (2018) have used the highest total number of sessions and strongest stimulation parameters,
413 including current intensity, compared to other investigations of the antidepressant effects of
414 transcranial electrical stimulation (Blumberger et al., 2012; Loo et al., 2012a; Palm et al.,
415 2012; Brunoni et al., 2013b; Bennabi et al., 2015), with both studies reporting no advantage
416 of active stimulation over sham.

417 The synaptic plasticity hypothesis of depression purports that MDD is characterized
418 by a partial reduction in long-term potentiation-like processes (Player et al., 2013; Kuhn et
419 al., 2016), suggesting that impaired synaptic plasticity, particularly in the prefrontal cortex, is
420 a key feature of the pathophysiology of depression (Goto et al., 2010; Duman et al., 2016;
421 Noda et al., 2018). This hypothesis is supported by evidence that the therapeutic efficacy of
422 antidepressants is, at least partly, due to their capacity to increase neural plasticity (Santarelli
423 et al., 2003; Castrén and Hen, 2013). Similarly, prior work from our group has demonstrated
424 that a course of tDCS increases neuroplasticity and mood outcomes in depression. However,
425 a correlation between these measures could not be confirmed due to the limited sample size
426 (n = 18) (Player et al., 2014b). Despite a larger sample size from which to detect small effects
427 of the intervention, we did not see an increase in neuroplasticity levels following tRNS.
428 Previous research has shown that tRNS can induce acute neuroplastic after-effects, measured
429 by investigating changes to motor cortex excitability using TMS motor evoked potentials
430 (Terney et al., 2008; Chaieb et al., 2015; Ho et al., 2015a). However, there is no evidence to

431 date to suggest cumulative changes in neuroplasticity following a course of multiple repeated
432 sessions of tRNS, as assessed in this study. An important caveat to our results is that only a
433 subset of participants (44/69) completed the PAS study. It is theoretically possible that the
434 subset of participants who underwent the PAS protocol had different clinical, physiological,
435 or behavioural characteristics (e.g. greater levels of motivation) and may thus not be
436 representative of the larger sample.

437 The exact purported mechanisms of action for prolonged cortical excitation following
438 tRNS are unclear, but may include either 1) temporal summation of neural activity when
439 random noise stimuli and ongoing endogenous neuronal activity occur in close succession
440 (Fertonani et al., 2011), and/or 2) enhancement of neuronal signalling via the principle of
441 stochastic resonance (van der Groen and Wenderoth, 2017). The latter refers to signals that
442 are too weak to exceed a threshold being amplified by adding a random noise stumulus,
443 improving the signal-to-noise ratio and the synchronization and coherence of neuronal
444 networks (Moss et al., 2004; Pavan et al., 2019). Though more research is required to
445 determine which of these mechanisms dominates, the action of tRNS appears to rely heavily
446 on detection and propagation of weak ongoing endogenous neuronal signals. The notion of
447 stochastic resonance has been demonstrated in several tRNS experiments aimed at enhancing
448 sensitivity to sensory inputs, including visual, auditory, and tactile stimuli (van der Groen and
449 Wenderoth, 2017). Interestingly, investigations of auditory (Rufener et al., 2017) and visual
450 (Van der Groen et al., 2018) perceptual thresholds have shown that tRNS has its largest effect
451 on near-threshold stimuli, whereas stimuli clearly above and below threshold were
452 unaffected. It may be for this reason that the only positive randomized control trials using
453 tRNS in clinical populations have stimulated the sensory and motor cortices, specifically in
454 the treatment of tinnitus via the auditory cortex (Vanneste et al., 2013), or stimulation of the
455 motor cortex for chronic pain in fibromyalgia (Curatolo et al., 2017). tRNS may restore the

456 dysfunctional activity in these cortical structures by normalizing their capacity to filter weak
457 signals amidst background neural noise. In complex disorders such as depression, however, it
458 is unclear what the depressed 'signal' might be. Studies seeking to use tRNS for other
459 complex disorders by stimulating prefrontal cortical regions have also reported negative
460 findings, i.e. for the treatment of multiple sclerosis (Palm et al., 2016b), and vegetative state
461 (Mancuso et al., 2017). Similarly to depression, these illnesses do not consist of a well-
462 defined neural signal whose signalling properties can be augmented by tRNS to revert
463 pathophysiological dysfunctions of brain activity.

464 Although the present study reports null findings for the use of tRNS in depression, it
465 provides valuable information regarding the safety and tolerability of multiple repeated
466 sessions of tRNS. To the best of our knowledge, the previous longest delivery of tRNS was
467 15 sessions (Chan et al., 2012), whereas participants in the current study experienced up to 40
468 sessions over eight weeks if allocated to the active tRNS condition. Adverse events of
469 erythema and paraesthesia were reported more frequently in the active tRNS condition as
470 compared to sham. These results are comparable to those observed in the tDCS literature, in
471 which meta-analyses similarly suggest a greater frequency of erythema and paraesthesia
472 (Moffa et al., 2017; Nikolin et al., 2018). Of interest, fatigue and dizziness/light-headedness
473 were also noted more frequently during active tRNS sessions. These side effects are not a
474 common adverse effect of tDCS and might be unique to the tRNS stimulation parameters
475 used in the current study, for example, due to the current intensity ranging as high as 3 mA (2
476 mA direct offset with ±1 mA amplitude fluctuation). Importantly, fatigue and dizziness/light-
477 headedness occurred rarely, in only 9.2% of sessions for fatigue, and 4.8% for light-
478 headedness. Additionally, these adverse events were transient, resolved on their own shortly
479 after cessation of stimulation, and were not reported to be severe in intensity.

A limitation of the present study is that blinding was not preserved, possibly due to the increased incidence of adverse events during active tRNS compared to sham. One would expect inadequate blinding to reduce placebo effects for participants in the sham condition, and potentially enhance them for participants receiving active tRNS, thereby increasing the likelihood of observing a difference between groups. This was not the case in the present study. Indeed, scores for mood outcomes were quantitatively (but not significantly) better in the sham condition compared to active tRNS, suggesting that inadequate blinding did not bias results in favour of the active treatment. Future studies may consider alternative methods to adequately blind participants, including the use of a topical salve beneath the site of stimulation to reduce paraesthetic effects and erythema (McFadden et al., 2011; Guarienti et al., 2015), or comparisons against an active control condition (Fonteneau et al., 2019).

A major strength of the present study is the research design, which included double blinding of participants and raters, examination of mood outcomes in addition to neuroplasticity changes, comprehensive assessment of adverse events using neuropsychological and physical measures, reporting of long-term follow-up outcomes up to 9-months following completion of the open-label phase, and rigorous statistical analysis methodology informed by CONSORT guidelines.

Conclusion

This study represents the first randomised control trial for the use of tRNS to treat depression. Our findings do not lend support for the use of tRNS as a therapeutic intervention for depression. Antidepressant response was similar between active and sham tRNS conditions. tRNS did not increase motor cortical excitability, a measure of neuroplasticity associated with antidepressant response in other successful therapeutic clinical trials of

504 depression (Santarelli et al., 2003; Castrén and Hen, 2013). The profile of adverse events for
505 tRNS was similar to that of tDCS, with a significantly greater likelihood of erythema and
506 paraesthesia in the active tRNS condition, in addition to a higher incidence rate of fatigue and
507 dizziness/light-headedness. Participant blinding was not preserved and may be related to the
508 increased frequency of side effects in the active condition. Overall, the treatment was well-
509 tolerated by participants.
510

511 ## Acknowledgements

512 This study was funded by a National Health and Medical Research Council
513 (NHMRC) Project Grant: APP1051423.
514

515 ## Statement of Interest

516 CL has served on a Janssen Advisory Board for Janssen and received an honorarium
517 from Mecta for teaching at an international electroconvulsive therapy (ECT) course. The
518 remaining authors have no conflicts of interest to declare.
519

References

Abe T, Miyaguchi S, Otsuru N, Onishi H (2019) The effect of transcranial random noise stimulation on corticospinal excitability and motor performance. Neuroscience letters 705:138-142.

Ambrus GG, Paulus W, Antal A (2010) Cutaneous perception thresholds of electrical stimulation methods: comparison of tDCS and tRNS. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 121:1908-1914.

Beck AT, Steer RA, Brown GK (1996) Manual for Beck Depression Inventory-II. San Antonio, TX: The Psychological Corporation.

Bennabi D, Nicolier M, Monnin J, Tio G, Pazart L, Vandel P, Haffen E (2015) Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopram. Clinical neurophysiology 126:1185-1189.

Bikson M et al. (2016) Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimulation 9:641-661.

Blumberger D, Tran L, Fitzgerald P, Hoy KB, Daskalakis ZJ (2012) A randomized double-blind sham-controlled study of transcranial direct current stimulation for treatment-resistant major depression. Frontiers in psychiatry 3:74.

Broadbent DE, Cooper PF, FitzGerald P, Parkes KR (1982) The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 21:1-16.

Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F (2011) A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. International Journal of Neuropsychopharmacology 14:1133-1145.

Brunoni AR, Ferrucci R, Bortolomasi M, Scelzo E, Boggio PS, Fregni F, Dell'Osso B, Giacopuzzi M, Altamura AC, Priori A (2013a) Interactions between transcranial direct current stimulation (tDCS) and pharmacological interventions in the Major Depressive Episode: findings from a naturalistic study. Eur Psychiatry 28:356-361.

Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA, Bensenor IM, Fregni F (2013b) The sertraline vs electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA psychiatry 70:383-391.

Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA, Bensenor IM, Fregni F (2013c) The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry 70:383-391.

Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP, Nogueira BS, Aparicio LV, Razza LB (2017) Trial of electrical direct-current therapy versus escitalopram for depression. New England Journal of Medicine 376:2523-2533.

Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D, Haffen E, Alonzo A, Loo CK (2016) Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry 208:522-531.

Castrén E, Hen R (2013) Neuronal plasticity and antidepressant actions. Trends in neurosciences 36:259-267.

Chaieb L, Antal A, Paulus W (2015) Transcranial random noise stimulation-induced plasticity is NMDA-receptor independent but sodium-channel blocker and benzodiazepines sensitive. Frontiers in neuroscience 9:125-125.

Chan HN, Alonzo A, Martin DM, Player M, Mitchell PB, Sachdev P, Loo CK (2012) Treatment of major depressive disorder by transcranial random noise stimulation: case report of a novel treatment. Biological psychiatry 72:e9-e10.

Contemori G, Trotter Y, Cottereau BR, Maniglia M (2019) tRNS boosts perceptual learning in peripheral vision. Neuropsychologia 125:129-136.

569 Curatolo M, La GB, Cosentino G, Baschi R, Salemi G, Talotta R, Romano M, Triolo G, De MT, Fierro B
570 (2017) Motor cortex tRNS improves pain, affective and cognitive impairment in patients with
571 fibromyalgia: preliminary results of a randomised sham-controlled trial. Clinical and
572 experimental rheumatology 35:100-105.
573 Delis DC, Kaplan E, Kramer JH (2001) Delis-Kaplan Executive Function System (D-KEFS). San Antonio,
574 TX: The Psychological Corporation.
575 Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California Verbal Learning Test (2nd ed.). San Antonio,
576 TX: The Psychological Corporation.
577 Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new
578 insights from stress and rapid-acting antidepressants. Nature medicine 22:238.
579 Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction
580 Questionnaire: a new measure. Psychopharmacol Bull 29:321-326.
581 Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ (2009) A
582 multidimensional tool to quantify treatment resistance in depression: the Maudsley staging
583 method. The Journal of clinical psychiatry 70:177-184.
584 Fertonani A, Pirulli C, Miniussi C (2011) Random noise stimulation improves neuroplasticity in
585 perceptual learning. The Journal of neuroscience : the official journal of the Society for
586 Neuroscience 31:15416-15423.
587 Fonteneau C, Mondino M, Arns M, Baeken C, Bikson M, Brunoni AR, Burke MJ, Neuvonen T, Padberg
588 F, Pascual-Leone A (2019) Sham tDCS: A hidden source of variability? Reflections for further
589 blinded, controlled trials. Brain stimulation.
590 Ghin F, Pavan A, Contillo A, Mather G (2018) The effects of high-frequency transcranial random noise
591 stimulation (hf-tRNS) on global motion processing: An equivalent noise approach. Brain
592 Stimul 11:1263-1275.
593 Goto Y, Yang CR, Otani S (2010) Functional and dysfunctional synaptic plasticity in prefrontal cortex:
594 roles in psychiatric disorders. Biological psychiatry 67:199-207.
595 Guarienti F, Caumo W, Shiozawa P, Cordeiro Q, Boggio PS, Benseñor IM, Lotufo PA, Bikson M,
596 Brunoni AR (2015) Reducing transcranial direct current stimulation-induced erythema with
597 skin pretreatment: considerations for sham-controlled clinical trials. Neuromodulation:
598 Technology at the Neural Interface 18:261-265.
599 Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD.: U.S. Department
600 of Health, Education, and Welfare.
601 Haesebaert F, Mondino M, Saoud M, Poulet E, Brunelin J (2014) Efficacy and safety of fronto-
602 temporal transcranial random noise stimulation (tRNS) in drug-free patients with
603 schizophrenia: a case study. Schizophrenia research 159:251-252.
604 Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015) Response of depression to
605 electroconvulsive therapy: a meta-analysis of clinical predictors. The Journal of clinical
606 psychiatry 76:1374-1384.
607 Hayward KS, Brauer SG, Ruddy KL, Lloyd D, Carson RG (2017) Repetitive reaching training combined
608 with transcranial Random Noise Stimulation in stroke survivors with chronic and severe arm
609 paresis is feasible: a pilot, triple-blind, randomised case series. Journal of neuroengineering
610 and rehabilitation 14:46.
611 Ho K-A, Taylor JL, Loo CK (2015a) Comparison of the effects of transcranial random noise stimulation
612 and transcranial direct current stimulation on motor cortical excitability. The journal of ECT
613 31:67-72.
614 Ho KA, Taylor JL, Loo CK (2015b) Comparison of the effects of transcranial random noise stimulation
615 and transcranial direct current stimulation on motor cortical excitability. The journal of ECT
616 31:67-72.
617 Inukai Y, Saito K, Sasaki R, Tsuiki S, Miyaguchi S, Kojima S, Masaki M, Otsuru N, Onishi H (2016)
618 Comparison of Three Non-Invasive Transcranial Electrical Stimulation Methods for Increasing
619 Cortical Excitability. Front Hum Neurosci 10:668-668.

Jooss A, Haberbosch L, Kohn A, Ronnefarth M, Bathe-Peters R, Kozarzewski L, Fleischmann R, Scholz M, Schmidt S, Brandt SA (2019) Motor Task-Dependent Dissociated Effects of Transcranial Random Noise Stimulation in a Finger-Tapping Task Versus a Go/No-Go Task on Corticospinal Excitability and Task Performance. Frontiers in neuroscience 13:161.

Kreuzer PM, Vielsmeier V, Poeppl TB, Langguth B (2017) A Case Report on Red Ear Syndrome with Tinnitus Successfully Treated with Transcranial Random Noise Stimulation. Pain physician 20:E199-e205.

Kuhn M, Mainberger F, Feige B, Maier JG, Mall V, Jung NH, Reis J, Klöppel S, Normann C, Nissen C (2016) State-dependent partial occlusion of cortical LTP-like plasticity in major depression. Neuropsychopharmacology 41:1521.

Liu W, Ge T, Leng Y, Pan Z, Fan J, Yang W, Cui R (2017) The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex. Neural Plast 2017:6871089.

Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012a) Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. The British Journal of Psychiatry 200:52-59.

Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012b) Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry 200:52-59.

Loo CK, Sachdev P, Martin D, Pigot M, Alonzo A, Malhi GS, Lagopoulos J, Mitchell P (2010) A double-blind, sham-controlled trial of transcranial direct current stimulation for the treatment of depression. Int J Neuropsychopharmacol 13:61-69.

Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM, McClintock SM, Mohan A (2018) International randomized-controlled trial of transcranial Direct Current Stimulation in depression. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation 11:125-133.

Mammarella N, Di Domenico A, Palumbo R, Fairfield B (2017) Self-generation and positivity effects following transcranial random noise stimulation in medial prefrontal cortex: A reality monitoring task in older adults. Cortex; a journal devoted to the study of the nervous system and behavior 91:186-196.

Mancuso M, Abbruzzese L, Canova S, Landi G, Rossi S, Santarnecchi E (2017) Transcranial random noise stimulation does not improve behavioral and neurophysiological measures in patients with subacute vegetative-unresponsive wakefulness state (VS-UWS). Frontiers in human neuroscience 11:524.

McFadden JL, Borckardt JJ, George MS, Beam W (2011) Reducing procedural pain and discomfort associated with transcranial direct current stimulation. Brain stimulation 4:38-42.

Moffa AH, Brunoni AR, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D, Haffen E, Alonzo A (2017) Safety and acceptability of transcranial direct current stimulation for the acute treatment of major depressive episodes: Analysis of individual patient data. Journal of affective disorders 221:1-5.

Moliadze V, Fritzsche G, Antal A (2014) Comparing the efficacy of excitatory transcranial stimulation methods measuring motor evoked potentials. Neural Plast 2014:837141-837141.

Montagne B, Kessels RP, De Haan EH, Perrett DI (2007) The Emotion Recognition Task: a paradigm to measure the perception of facial emotional expressions at different intensities. Perceptual and motor skills 104:589-598.

Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.

Moss F, Ward LM, Sannita WG (2004) Stochastic resonance and sensory information processing: a tutorial and review of application. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 115:267-281.

Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY (2018) Efficacy and acceptability of non-invasive brain stimulation for the treatment of adult unipolar and bipolar depression: A systematic review

671 and meta-analysis of randomised sham-controlled trials. Neuroscience and biobehavioral
672 reviews 92:291-303.
673 Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK (2017) Safety of repeated sessions of transcranial
674 direct current stimulation: A systematic review. Brain Stimulation.
675 Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK (2018) Safety of repeated sessions of transcranial
676 direct current stimulation: A systematic review. Brain Stimulation: Basic, Translational, and
677 Clinical Research in Neuromodulation 11:278-288.
678 Nitsche M, Paulus W (2001) Sustained excitability elevations induced by transcranial DC motor
679 cortex stimulation in humans. Neurology 57:1899-1901.
680 Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, Paulus W, Hummel F, Boggio PS,
681 Fregni F, Pascual-Leone A (2008) Transcranial direct current stimulation: State of the art
682 2008. Brain Stimul 1:206-223.
683 Noda Y, Zomorrodi R, Vila-Rodriguez F, Downar J, Farzan F, Cash RF, Rajji TK, Daskalakis ZJ,
684 Blumberger DM (2018) Impaired neuroplasticity in the prefrontal cortex in depression
685 indexed through paired associative stimulation. Depression and anxiety 35:448-456.
686 Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E, Pogarell O, Nitsche M, Möller H-J,
687 Padberg F (2012) Transcranial direct current stimulation in treatment resistant depression: a
688 randomized double-blind, placebo-controlled study. Brain stimulation 5:242-251.
689 Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, Dimitri D, Creange A, Lefaucheur JP,
690 Ayache SS (2016a) Effects of transcranial random noise stimulation (tRNS) on affect, pain
691 and attention in multiple sclerosis. Restorative neurology and neuroscience 34:189-199.
692 Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, Dimitri D, Créange A, Lefaucheur J-P,
693 Ayache SS (2016b) Effects of transcranial random noise stimulation (tRNS) on affect, pain
694 and attention in multiple sclerosis. Restorative neurology and neuroscience 34:189-199.
695 Pavan A, Ghin F, Contillo A, Milesi C, Campana G, Mather G (2019) Modulatory mechanisms
696 underlying high-frequency transcranial random noise stimulation (hf-tRNS): A combined
697 stochastic resonance and equivalent noise approach. Brain Stimul.
698 Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms.
699 Neuropsychopharmacology : official publication of the American College of
700 Neuropsychopharmacology 33:88-109.
701 Player MJ, Taylor JL, Alonzo A, Loo CK (2012) Paired associative stimulation increases motor cortex
702 excitability more effectively than theta-burst stimulation. Clinical neurophysiology : official
703 journal of the International Federation of Clinical Neurophysiology 123:2220-2226.
704 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev P, Martin D, Mitchell PB, Loo CK (2013)
705 Neuroplasticity in depressed individuals compared with healthy controls.
706 Neuropsychopharmacology 38:2101.
707 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev PS, Martin D, Mitchell PB, Loo CK (2014a)
708 Increase in PAS-induced neuroplasticity after a treatment course of transcranial direct
709 current stimulation for depression. J Affect Disord 167:140-147.
710 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev PS, Martin D, Mitchell PB, Loo CK (2014b)
711 Increase in PAS-induced neuroplasticity after a treatment courseof transcranial direct
712 current stimulation for depression. Journal of affective disorders 167:140-147.
713 Popescu T, Krause B, Terhune DB, Twose O, Page T, Humphreys G, Cohen Kadosh R (2016)
714 Transcranial random noise stimulation mitigates increased difficulty in an arithmetic learning
715 task. Neuropsychologia 81:255-264.
716 Rufener KS, Ruhnau P, Heinze H-J, Zaehle T (2017) Transcranial random noise stimulation (tRNS)
717 shapes the processing of rapidly changing auditory information. Frontiers in cellular
718 neuroscience 11:162.
719 Rufener KS, Geyer U, Janitzky K, Heinze HJ, Zaehle T (2018) Modulating auditory selective attention
720 by non-invasive brain stimulation: Differential effects of transcutaneous vagal nerve

721 stimulation and transcranial random noise stimulation. The European journal of
722 neuroscience 48:2301-2309.
723 Ruff RM, Allen CC (1996) Ruff 2 and 7 Selective Attention Test Professional Manual. Odessa, FL:
724 Psychological Assessment Resources, Inc.
725 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME,
726 Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M
727 (2006) Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several
728 Treatment Steps: A STAR*D Report. Am J Psychiatry 163:1905-1917.
729 Salemi G, Vazzoler G, Ragonese P, Bianchi A, Cosentino G, Croce G, Gangitano M, Portera E,
730 Realmuto S, Fierro B, Brighina F (2019) Application of tRNS to improve multiple sclerosis
731 fatigue: a pilot, single-blind, sham-controlled study. Journal of neural transmission (Vienna,
732 Austria : 1996).
733 Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O
734 (2003) Requirement of hippocampal neurogenesis for the behavioral effects of
735 antidepressants. science 301:805-809.
736 Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting
737 parallel group randomised trials. BMC medicine 8:18.
738 Shalev N, De Wandel L, Dockree P, Demeyere N, Chechlacz M (2018) Beyond time and space: The
739 effect of a lateralized sustained attention task and brain stimulation on spatial and selective
740 attention. Cortex; a journal devoted to the study of the nervous system and behavior
741 107:131-147.
742 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC
743 (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and
744 validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The
745 Journal of clinical psychiatry 59 Suppl 20:22-33;quiz 34-57.
746 Smith A (1991) Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services.
747 Snowball A, Tachtsidis I, Popescu T, Thompson J, Delazer M, Zamarian L, Zhu T, Kadosh RC (2013)
748 Long-term enhancement of brain function and cognition using cognitive training and brain
749 stimulation. Current Biology 23:987-992.
750 Stefan K, Wycislo M, Classen J (2004) Modulation of associative human motor cortical plasticity by
751 attention. Journal of neurophysiology 92:66-72.
752 Szymkowicz SM, McLaren ME, Suryadevara U, Woods AJ (2016) Transcranial Direct Current
753 Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review. Psychiatric
754 annals 46:642-646.
755 Terney D, Chaieb L, Moliadze V, Antal A, Paulus W (2008) Increasing human brain excitability by
756 transcranial high-frequency random noise stimulation. Journal of Neuroscience 28:14147-
757 14155.
758 Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH,
759 Lebowitz B, McGrath PJ (2006) Evaluation of outcomes with citalopram for depression using
760 measurement-based care in STAR* D: implications for clinical practice. American journal of
761 Psychiatry 163:28-40.
762 Tyler SC, Conto F, Battelli L (2018) Rapid Improvement on a Temporal Attention Task within a Single
763 Session of High-frequency Transcranial Random Noise Stimulation. Journal of cognitive
764 neuroscience 30:656-666.
765 van der Groen O, Wenderoth N (2017) Random noise stimulation of the cortex: stochastic resonance
766 enhances central mechanisms of perception. Brain Stimulation: Basic, Translational, and
767 Clinical Research in Neuromodulation 10:e4.
768 Van der Groen O, Tang MF, Wenderoth N, Mattingley JB (2018) Stochastic resonance enhances the
769 rate of evidence accumulation during combined brain stimulation and perceptual decision-
770 making. PLoS computational biology 14:e1006301.

Vanneste S, Fregni F, De Ridder D (2013) Head-to-head comparison of transcranial random noise stimulation, transcranial AC stimulation, and transcranial DC stimulation for tinnitus. Frontiers in psychiatry 4:158.

Wechsler D (2008) Wechsler Adult Intelligence Scale (4th ed.). San Antonio, TX: Pearson.

Supplementary Materials

Paired associative stimulation methods

Participants sat in a comfortable, relaxed position with both hands on a pillow. The optimal site for eliciting motor evoked potentials (MEPs) in the right first dorsal interosseous (FDI) muscle was first established and marked on the scalp. Each participant's resting motor threshold (RMT) – defined as the minimum stimulus intensity to evoke MEPs of ⩾50 μV in the relaxed FDI in 5 out of 10 consecutive trials of single-pulse TMS – was then measured. TMS intensity for evoking test MEPs was adjusted individually for each participant to elicit an average 1 mV response. TMS intensity for testing MEPs was limited to a maximum of 130% of RMT even if the actual intensity needed to elicit a 1 mV response was greater.

For the stimulation protocol, single-pulse TMS (130% of RMT) to the FDI representation on the left motor cortex was combined with electrical stimuli (200 μs duration, 300% perceptual threshold, DS7 stimulator; Digitimer Co. Ltd., Hertfordshire, UK) to the right ulnar nerve proximal to the wrist. Two hundred pairs of stimuli (TMS and ulnar nerve) were given at 0.25 Hz over ~13 minutes. In each pair, ulnar nerve stimulation preceded TMS by 25 ms. Electrical stimuli were delivered occasionally to the right index finger during PAS. Participants counted the stimuli and reported the number at the end of the session to ensure sensory attention to the hand (Stefan et al., 2004). The MEPs recorded before and after PAS to assess cortical excitability consisted of testing blocks of 20 MEPs at a rate of 0.1 Hz. Two blocks of MEPs were recorded at baseline. A block of MEPs was recorded immediately after PAS and then every 10 mins for one hour. During all stimulation, EMG from the FDI was monitored to ensure muscle relaxation. MEPs were discarded if EMG showed substantial muscle activity (i.e. peak-to-peak amplitude ≥ 50 μV) in the time window prior to the TMS stimuli. Additionally, block-averaged MEP amplitudes were considered outliers if they were

more than 4 standard deviations from the mean for active and sham tRNS conditions combined.

EMG activity was recorded through Ag/AgCl surface electrodes over the right FDI. EMG was amplified, bandpass filtered (16–1000 Hz), and digitized (2000 Hz) (Cambridge Electronics Design, Cambridge, UK). TMS (Magstim 200 stimulator, Magstim Co., Whitland, UK) was applied using a 70-mm figure-of eight coil oriented with the handle posterolateral, 45° to the parasagittal plane.

807 ## Supplementary Table S1. Schedule of assessments.

	Baseline	Sham-controlled phase				Open-label phase				Taper phase			
Week	Wk 0	Wk 1	Wk 2	Wk 3	Wk 4	Wk 1	Wk 2	Wk 3	Wk 4	Wk 1	Wk 2	Wk 3	Wk 4
Session	Pre 1	1-5	6-10	11-15	16-20	21-25	26-30	31-35	36-40	41	42	43	44
Mood Assessments													
MADRS	X		X		X		X		X				X
BDI-II	X	X	X	X	X	X	X	X	X	X	X	X	X
CGI-S	X												
CGI-I			X		X		X		X				X
Q-LES-SF	X				X				X				X
Neurophysiological Assessments													
PAS	X				X				X				
Neuropsychological Assessments													
CVLT-II	X				X				X				
Ruff 2 & 7	X				X				X				
WAIS-IV Digit Span	X				X				X				
SDMT	X				X				X				
D-KEFS Verbal Fluency	X				X				X				
CFQ	X				X				X				

808 Wk: Week. MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale
809 ranked from 1-normal to 7-extremely ill. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse. Q-
810 LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult
811 Intelligence Scale. SDMT: Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire

812 ## Supplementary Table S2. Intention-to-treat analyses.

813 Estimated marginal means and results from MERM analyses during the sham-controlled phase, including the following covariates: Maudsley
814 staging parameters total score as a measure of treatment resistance, and antidepressant use. Mood, quality of life, neuroplasticity, and
815 neuropsychological outcome measures are reported using an intention-to-treat analysis approach.

	Baseline		Week 2		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	Sham	Active	F	p	F	p	F	p
Mood Assessments (m, SEM)												
MADRS	29.1 (0.8)	29.0 (0.8)	24.4 (1.0)	24.8 (1.1)	22.1 (1.2)	23.7 (1.3)	0.29	0.593	43.09	**<0.001**	0.77	0.467
BDI-II	32.4 (1.6)	33.4 (1.7)	24.9 (1.9)	27.1 (2.0)	21.9 (1.9)	25.1 (2.0)	1.07	0.306	25.07	**<0.001**	0.58	0.678
CGI-I	-	-	3.5 (0.1)	3.6 (0.1)	3.1 (0.1)	3.4 (0.1)	2.60	0.112	13.07	**<0.001**	1.98	0.165
Q-LES-SF	32.5 (1.8)	35.8 (2.0)	-	-	43.6 (2.8)	43.8 (2.9)	0.37	0.545	32.00	**<0.001**	0.80	0.376
Neuroplasticity Assessments (m, SEM)												
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	-	-	1.31 (0.09)	1.40 (0.10)	0.08	0.780	1.63	0.209	0.33	0.570
Neuropsychological Assessments (m, SEM)												
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.2)	48.8 (2.2)	-	-	46.3 (2.3)	49.7 (2.1)	2.29	0.133	0.10	0.751	0.01	0.943
CVLT-II: Long delay free recall z-score	-0.42 (0.21)	0.03 (0.21)	-	-	-0.64 (0.22)	-0.39 (0.21)	2.82	0.096	1.93	0.167	0.23	0.635
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.6 (0.7)	-	-	10.9 (0.7)	11.9 (0.7)	1.18	0.280	0.00	0.991	0.21	0.648
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	-	-	9.9 (0.8)	11.7 (0.8)	1.64	0.204	0.07	0.789	1.78	0.187
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.2 (0.6)	-	-	9.6 (0.6)	10.6 (0.6)	3.61	0.060	0.56	0.454	0.04	0.850
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	50.6 (1.9)	-	-	51.4 (1.9)	53.6 (1.9)	2.17	0.144	2.97	0.087	0.07	0.789
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.5 (2.3)	-	-	50.4 (2.4)	48.7 (2.3)	1.07	0.302	0.36	0.547	0.09	0.764
SDMT: Total correct z-score	-0.31 (0.17)	0.22 (0.18)	-	-	0.00 (0.18)	0.40 (0.17)	4.10	**0.047**	4.38	**0.039**	0.53	0.469
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.5)	-	-	10.5 (0.6)	12.6 (0.5)	13.67	**<0.001**	2.50	0.116	0.09	0.771

CFQ: Total score	50.1 (2.2)	46.6 (2.2)	-	-	49.9 (2.3)	50.0 (2.2)	0.61	0.435	0.45	0.501	0.70	0.406

MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation. MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measures

820 Supplementary Table S3. MADRS mixed-effects repeated measures analyses

821 using other covariates.

822 Results from MERM analyses during the sham-controlled phase to examine the impact of

823 medications and treatment expectations as covariates on mood outcomes (i.e. MADRS

824 scores).

	Covariate		Time		Condition		Time x Condition	
	F	p	F	p	F	p	F	p
Baseline TEQ	0.28	0.599	40.93	**<0.001**	0.99	0.325	1.32	0.276
Antidepressants	1.14	0.289	44.28	**<0.001**	2.03	0.160	1.11	0.335
Lithium	3.73	0.058	44.20	**<0.001**	2.24	0.140	1.14	0.327
Benzodiazepine*	2.48	0.120	44.24	**<0.001**	1.88	0.175	1.12	0.332
Antipsychotics	1.78	0.188	44.22	**<0.001**	2.15	0.147	1.12	0.332
Anticonvulsants	0.34	0.561	44.26	**<0.001**	2.10	0.152	1.12	0.332

825 *Participants were required to cease benzodiazepine medication use prior to commencing the trial.
826 TEQ: Treatment Expectations Questionnaire

827 Supplementary Table S4. Mood, quality of life, neuroplasticity and

828 neuropsychological outcome measures.

829 Results from MERM analyses during the acute daily treatment phases combined (i.e. tRNS

830 received during the sham-controlled and open-label phases).

	Condition		Time		Time × Condition	
	F	p	F	p	F	p
Mood Assessments (m, SEM)						
MADRS	1.09	0.300	29.39	**<0.001**	0.75	0.560
BDI-II	2.38	0.128	17.60	**<0.001**	1.00	0.447
CGI-I	6.02	**0.017**	15.84	**<0.001**	1.72	0.173
Q-LES-SF	0.00	0.967	30.00	**<0.001**	1.39	0.257
Neuroplasticity Assessments (m, SEM)						
PAS: MEP amplitude	0.40	0.530	2.11	0.135	0.72	0.193
Neuropsychological Assessments (m, SEM)						
CVLT-II: Trial 1-5 total recall t-score	4.47	**0.036**	3.12	**0.046**	0.17	0.844
CVLT-II: Long delay free recall z-score	5.40	**0.021**	3.03	0.051	0.23	0.799
D-KEFS: Letter fluency scaled score	2.70	0.102	0.14	0.867	0.38	0.683
D-KEFS: Category fluency scaled score	1.97	0.165	0.74	0.477	1.69	0.190
D-KEFS: Category switching total scaled score	2.94	0.088	1.07	0.346	0.24	0.786
Ruff 2 & 7: Total speed t-score	2.94	0.088	3.50	**0.032**	0.06	0.946
Ruff 2 & 7: Total accuracy t-score	0.80	0.372	0.73	0.482	0.22	0.805
SDMT: Total correct z-score	3.58	0.063	2.80	0.065	1.11	0.335
WAIS-IV Digit Span: Total correct scaled score	17.17	**<0.001**	2.05	0.132	0.06	0.945
CFQ: Total score	0.20	0.659	0.12	0.891	0.45	0.639

831 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global
832 Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse.
833 Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation.
834 MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT:
835 Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire.
836 m: Mean. SEM: Standard error of measures

837 Supplementary Figure S1. Treatment Expectations Questionnaire

Treatment Expectations Questionnaire – Views on DCS

Participant ID _____ Date _____ Session _____

Please answer the following questions about how effective you think DCS will be in helping improve some symptoms of depression you may be experiencing. If you are not currently experiencing the symptom, please circle NA.

1) How effective do you think DCS will be for improving your **sleep?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with sleep

2) How effective do you think DCS will be for reducing **feelings of sadness?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with feeling sad

3) How effective do you think DCS will be for improving your **appetite?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with my appetite

4) How effective do you think DCS will be for improving your **concentration/decision making?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with concentration/ decision making

5) How effective do you think DCS will be for reducing **thoughts of death or suicide?**

838

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with thoughts of death or suicide

6) How effective do you think DCS will be for improving your **general interest in things and/or your ability to enjoy things?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with general interest/ enjoying things

7) How effective do you think DCS will be for improving your **energy level?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with my energy levels

8) **OVERALL**, how effective do you think DCS will be for helping to improve the symptoms you are currently experiencing?

1	2	3	4	5
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective

9) Are there any particular reasons why you believe DCS will or will not be effective?

_____

_____

_____

_____

_____

_____

839

END OF QUESTIONNAIRE

840

841 Supplementary Figure S2. tRNS Side Effects Questionnaire

Side Effect	Before	During	After	Severity*	Causality#
Redness **anode cathode**					
Tingling/Itching/Burning/Pain **anode cathode**					
Nausea					
Lightheadedness/Dizziness					
Headache					
Blurred Vision					
Fatigue					
Other:					

***Severity: 1 = Mild; 2 = Moderate; 3 = Severe. If participant had a side effect after the previous tRNS session, ask when it started and for how long and record in the 'Before' column.**
#Causality: 1 = Probably Related; 2 = Possibly Related; 3 = Probably Not Related; 4 = Not Related

842

843 Supplementary Figure S3. CONSORT flow diagram.

844 The study was registered at:

845 https://clinicaltrials.gov/ct2/show/NCT01792414 (ID: NCT01792414).



846

847 Supplementary Figure S4. Follow-up mood outcome measures.

848 Graphs showing mood and quality of life scores (unadjusted means ± SD) from baseline up to
849 the 9-month follow-up assessment following completion of the open-label phase. Sample
850 sizes used for the calculation of summary statistics are presented for each time-point. **A)**
851 Montgomery-Asberg Depression Rating Scale (MADRS) scores. **B)** Beck Depression
852 Inventory (BDI-II) scores. **C)** Clinician Global Impression Severity (CGI-S) at baseline, and
853 CGI-Improvement (CGI-I) scores; the CGI-S is a 7-point clinician-rated scale ranked from 1-
854 normal (not at all ill) to 7-among most extremely ill patients. The CGI-I is a 7-point clinician-
855 rated scale ranked from 1-very much improved to 7-very much worse. **D)** Quality of Life
856 Enjoyment and Satisfaction Questionnaire – Short Form scores (Q-LES-SF).



857


B
BDI score
50
40
30
20
10
0
Sham
Active
Baseline
1 Week
2 Weeks
3 Weeks
4 Weeks
5 Weeks
6 Weeks
7 Weeks
8 Weeks
1w f/up
2w f/up
3w f/up
1m f/up
3m f/up
6m f/up
9m f/up

858


C
CGI score
6
4
2
0
Sham
Active
Baseline (CGI-S)
2 Weeks
4 Weeks
6 Weeks
8 Weeks
1m f/up
3m f/up
6m f/up
9m f/up

859


D
Q-LES-SF score
100
80
60
40
20
0
Sham
Active
35
32
32
31
30
30
16
20
11
16
9
11
2
Baseline
4 Weeks
8 Weeks
1m f/up
3m f/up
6m f/up
9m f/up

Supplementary Figure S5. Paired associative stimulation.

Group data (estimated marginal means ± bootstrapped 95% confidence intervals) showing the time course of changes in the amplitude of motor evoked potentials (MEPs) immediately after the PAS conditioning stimulus. Post-PAS MEP amplitudes were normalized to pre-PAS amplitudes for each participant. **A)** MEP amplitude changes at baseline, prior to the course of tRNS. **B)** MEP amplitude changes following the 4-week sham-controlled phase.



869 Supplementary Figure S6. Correlation between mood and neuroplasticity.

870 There was no association between percent change in motor evoked potentials (MEPs)

871 following paired associative stimulation (PAS) and percent change in mood scores over the

872 course of the sham-controlled phase (r = -0.02, p = 0.905).



873

874